2017 Fiscal Year Final Research Report
New approach to improve delivery of anticancer drugs by modulating extracellular matrix in musculoskeletal tumors
Project/Area Number |
15K10452
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Orthopaedic surgery
|
Research Institution | Kagoshima University |
Principal Investigator |
NAGANO Satoshi 鹿児島大学, 医歯学域医学系, 准教授 (50373139)
|
Co-Investigator(Kenkyū-buntansha) |
小宮 節郎 鹿児島大学, 医歯学域医学系, 教授 (30178371)
瀬戸口 啓夫 鹿児島大学, 医歯学総合研究科, 特任准教授 (40423727)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Keywords | 骨軟部腫瘍 / 細胞外マトリックス / アンジオテンシン経路 / Tranilast / 細胞周期 |
Outline of Final Research Achievements |
To explore a new treatment for musculoskeletal tumor (MST), we focused on drugs that reduces extracellular matrix (ECM). However, we found no significant role of angiotensin pathway drugs in ECM of MST. Therefore we next focused on anti-allergic drug tranilast, which is known to modulate ECM production by fibroblast. Tranilast inhibited proliferation of osteosarcoma cells in a dose-dependent manner. Combined treatment with tranilast and anti-cancer agents enhanced the cytotoxic effect on osteosarcoma cells. Tranilast enhanced the effect of cisplatin on growth of osteosarcoma xenograft in mice. Because tranilast has been used in clinics without severe side effects for many patients, clinical application in cancer therapy is expected.
|
Free Research Field |
骨軟部腫瘍学、遺伝子治療学
|